

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.: 10/789,627

Applicants: Kaufman et al.

Filed: February 26, 2004

Confirmation No.: 7662

Group Art Unit: 1632

Examiner: Anoop Kumar Singh

Title: Composition for Delivering an Agent to a Target Cell and Uses thereof

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT IN RESPONSE TO MAY 18, 2007 NON-FINAL OFFICE ACTION

This paper is being filed in reply to the May 18, 2007 Office Action issued by the U.S. Patent and Trademark Office. A response was originally due on August 18, 2007 and Applicants hereby request a three-month extension of time from August 18, 2007 to November 18, 2007. Therefore, this paper is being filed timely.

Amendments to the Claims begins on page 3 of this paper.

Remarks begin on page 10 of this paper.

This submission also includes:

- 1) Declaration under 37 C.F.R. §1.132 executed by the inventors Howard Kaufman and Michal Bereta;
- 2) Exhibit A [submitted herewith an IDS]: Toso et al., “Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma” (2002) *J Clin Oncol.* 20(1):142-52;
- 3) Exhibit B [submitted herewith an IDS]: Medina and Guzman, “Use of live bacterial vaccine vectors for antigen delivery: potential and limitations,” (2001) *Vaccine* 19:1573-80;
- 4) Exhibit C [submitted herewith an IDS]: Chang et al., “Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium,” (1992) *Cancer Res.* 52(1):181-6 ; and

- 5) Exhibit D [submitted herewith an IDS]: Lee et al., “Cdk4 and p27^{Kip1} play a role in PLC-g1-mediated mitogenic signaling pathway of 18 kDa FGF-2 in corneal endothelial cells”(2002) *Mol Vis.* 8:17-25.